Moleculin Enters New Collaboration Agreement for Drug Combination

Moleculin Biotech (NASDAQ:MBRX) entered into a collaborative agreement with the University of Bergen to test WP1122 in combination with Roche Pharma’s drug Avastin(R).
As quoted in the press release:

Roche Pharma is not a party to the collaborative agreement.
“The potential for synergy with Roche’s drug is compelling,” commented Walter Klemp, Chairman and CEO of Moleculin. “Avastin showed early promise in the treatment of brain tumors, but its usefulness has been hampered by the ability of brain tumors to develop resistance to anti-vascular therapy. Avastin prevents formation of new blood vessels including blood vessels that feed growing tumors and, as such, creates an environment where tumors become more dependent on glycolysis (a means of producing energy induced by a limited oxygen supply from the blood) enabling a potential form of therapy resistance.

Click here to read the full press release.

Source: www.marketwired.com